Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Hikma Pharmaceuticals ( (GB:HIK) ) is now available.
Hikma Pharmaceuticals has disclosed a series of share-related transactions involving its senior leadership and a closely associated entity, Darhold Limited, in line with market abuse regulations. On 19 December 2025, Darhold released a pledge over 2.5 million Hikma ordinary shares previously in favour of Bank Julius Baer and, on the same day, granted a new pledge over the same number of shares in favour of Europe Arab Bank, with identical transactions reported in relation to Executive Chairman and CEO Said Darwazah, Executive Vice Chairman Mazen Darwazah and non-executive director Ali Al‑Husry. The moves, which were executed at a reported price of zero, indicate a refinancing or reorganisation of security arrangements over a substantial block of insider-linked shares, but do not change the overall number of Hikma shares in issue, and are therefore more relevant to understanding the directors’ personal financing structures and governance transparency than to the company’s immediate capital position.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1793.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on GB:HIK Stock
According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.
Hikma Pharmaceuticals’ overall stock score is driven by strong financial performance and attractive valuation. While technical indicators suggest a bearish trend, the company’s strategic achievements and executive confidence provide a positive outlook. Earnings call insights and corporate events further support the stock’s potential for growth.
To see Spark’s full report on GB:HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a London-listed pharmaceutical company that focuses on the development, manufacturing and marketing of generic and branded medicines. The group serves global markets, with a particular strength in injectable and oral treatments across the US, Europe, the Middle East and North Africa.
Average Trading Volume: 743,709
Technical Sentiment Signal: Sell
Current Market Cap: £3.34B
For an in-depth examination of HIK stock, go to TipRanks’ Overview page.